- Home
- CRSP vs PAYO Comparison
CRSP vs PAYO Comparison
Compare CRSP & PAYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- PAYO
- Stock Information
- Founded
- CRSP 2013
- PAYO 2005
- Country
- CRSP Switzerland
- PAYO United States
- Employees
- CRSP N/A
- PAYO N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- PAYO EDP Services
- Sector
- CRSP Health Care
- PAYO Technology
- Exchange
- CRSP Nasdaq
- PAYO Nasdaq
- Market Cap
- CRSP 4.3B
- PAYO 3.7B
- IPO Year
- CRSP 2016
- PAYO N/A
- Fundamental
- Price
- CRSP $43.65
- PAYO $10.34
- Analyst Decision
- CRSP Buy
- PAYO Strong Buy
- Analyst Count
- CRSP 18
- PAYO 7
- Target Price
- CRSP $76.60
- PAYO $11.36
- AVG Volume (30 Days)
- CRSP 1.8M
- PAYO 2.7M
- Earning Date
- CRSP 11-05-2024
- PAYO 11-05-2024
- Dividend Yield
- CRSP N/A
- PAYO N/A
- EPS Growth
- CRSP N/A
- PAYO 118.00
- EPS
- CRSP N/A
- PAYO 0.34
- Revenue
- CRSP $202,829,000.00
- PAYO $940,297,000.00
- Revenue This Year
- CRSP N/A
- PAYO $17.47
- Revenue Next Year
- CRSP $758.18
- PAYO $8.27
- P/E Ratio
- CRSP N/A
- PAYO $30.31
- Revenue Growth
- CRSP 19.31
- PAYO 18.97
- 52 Week Low
- CRSP $42.86
- PAYO $4.22
- 52 Week High
- CRSP $91.10
- PAYO $11.29
- Technical
- Relative Strength Index (RSI)
- CRSP 39.11
- PAYO 50.66
- Support Level
- CRSP $43.40
- PAYO $10.25
- Resistance Level
- CRSP $53.97
- PAYO $10.58
- Average True Range (ATR)
- CRSP 2.37
- PAYO 0.26
- MACD
- CRSP -0.78
- PAYO -0.12
- Stochastic Oscillator
- CRSP 9.53
- PAYO 26.55
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About PAYO Payoneer Global Inc.
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.